2011年非酒精性脂肪性肝病治疗进展

doi:10.3969/j.issn.1672-5069.2012.02.002

[1] Cao HX,Fan JG. Fatty liver disease:a growing public health problem worldwide. J Dig Dis,2011,12:1-2.
[2] Sanyal AJ,Brunt EM,Kleiner DE,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-353.
[3] Haufe S,Engeli S,Kast P,et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology,2011,53:1504-1514.
[4] Hallsworth K,Fattakhova G,Hollingsworth KG,et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut,2011,60:1278-1283.
[5] Torres DM,Jones FJ,Shaw JC,et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans:A 12-month randomized,prospective,open- label trial. Hepatology,2011,54:1631-1639.
[6] O’Shea RS,Dasarathy S,McCullough AJ. Alcoholic liver disease. AASLD Practice Guidelines. Hepatology,2010,51:307-328.
[7] Zein CO,Yerian LM,Gogate P,et al. Pentoxifylline improves nonalcoholic steatohepatitis:A randomized placebo-controlled trial. Hepatology 2011;54:1610-1619.
[8] Ratziu V,Sheikh MY,Sanyal AJ,et al. A phase 2,randomized, double-blind,placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology,2011,[Epub ahead of print]
[9] Ratziu V,de Ledinghen V,Oberti F,et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol,2011,54:1011-1019.
[10] Thoma C,Day CP,Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults:A systematic review. J Hepatol,2011,[Epub ahead of print]
[11] Mahady SE,Webster AC,Walker S,et al. The role of thiazolidinediones in non-alcoholic steatohepatitis：A systematic review and meta analysis. J Hepatol,2011,55:1383-1390.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[6]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[7]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[10]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[11]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[12]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments